SCHEMBL6416210

SCHEMBL6416210

COc1cccc(CCNC(=O)CCN2C(=O)c3ccccc3C(C(=O)NCc3ccccc3)C2c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 1/20 0.42
IDO1 P14902 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNH2 Q12809 2/20 0.42
SCN9A Q15858 2/20 0.42
SCN5A Q14524 1/20 0.42
FFAR1 O14842 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411387 0.92 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTHTTLMNA
SCHEMBL6416211 0.84 KMT2A (0.42) HSD17B10ALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL6410919 0.81 TSHR (0.45) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL2938982 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTHTTLMNA
SCHEMBL6418322 0.80 HSD17B10 (0.55) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL6416285 0.78 HSD17B10 (0.50) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL6411734 0.77 CCR2 (0.41) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL6415209 0.77 SCN9A (0.41) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL6411391 0.77 ALDH1A1 (0.45) ALDH1A1KDM4EMAPTHTTLMNA
SCHEMBL6413158 0.77 SCN9A (0.41) HSD17B10ALDH1A1KDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD HSD17B10 1460/4885ALDH1A1 1368/4885KDM4E 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.